关于eptinezumab治疗偏头痛的有效性和安全性:系统性审查和元分析
Yi Zhong1, Jiahe Wang2, Hang Li1
1Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu, China.
概括
与安慰剂相比,eptinezumab有效地减少了偏头痛的频率,并改善了应答率. 这种CGRP抗剂表现出良好的疗效,不显著增加不良事件,特别是在300毫克的剂量.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 素基因相关 (CGRP) 已因其在偏头痛病理生理学中的作用而得到认可.
- 埃普特尼祖马布代表了一种用于治疗偏头痛的新型CGRP抗剂.
研究的目的:
- 系统地审查和比较eptinezumab与安慰剂治疗偏头痛的疗效和安全性.
- 评估eptinezumab对偏头痛关键指标和不良事件概况的影响.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane Library,ClinicalTrials.gov) 进行了系统的文献搜索,截至2023年2月16日.
- 四个随机对照试验 (RCT) 涉及2,739名患者被纳入了元分析.
- 平均差异 (MD) 和风险比率 (RR) 用于分析临床结果和安全数据.
主要成果:
- 与安慰剂相比,eptinezumab显著减少了每月偏头痛日 (MD = -1.56) 和改善了响应率 (≥50%,≥75%,100%).
- 300毫克的剂量显示出特别的疗效 (P<0.001),而10毫克的剂量没有显著的效果.
- 没有观察到与治疗相关的不良事件 (RR = 1.01) 或严重不良事件 (RR = 0.93) 的显著增加.
结论:
- 埃普特尼祖马布在偏头痛治疗中表现出显著的治疗效果,特别是减少偏头痛的频率并增强患者的反应.
- 与安慰剂相比,eptinezumab的安全性概况是有利的,并没有显著增加不良事件.
- 300毫克的eptinezumab剂量因其在偏头痛管理中的实质性有效性而受到重视.
相关概念视频
01:30Electroconvulsive Therapy
41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
01:14Antiepileptic Drugs: Glutamate Antagonists
359
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
359